Is it worth buying Moderna stock at a price of $27.76? If this question is on your mind, make sure to check out the fundamentals of this Biotechnology Large-Cap company: Moderna has logged a -82.0% 52 ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

(Reuters) -Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune ...

Findings indicate that frequent COVID-19 booster shots do not weaken T-cell responses, alleviating concerns for vulnerable ...

Moderna shares advanced after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast. Covid vaccine sales totaled $1.8 ...

Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that provides messenger RNA medicines worldwide. With a market cap of $10.6 billion, the company’s diverse ...

The talks are the first hint that Merck is returning to the negotiating table a year after buying EyeBio in its last multibillion-dollar biotech deal. Its shares have fallen 39% over the past year ...

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine ...

Now the biotech is caught in the crossfire of Trump 2.0 as vaccine-making comes under fire. In the latest setback for Moderna, the Food and Drug Administration on Friday approved its next ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules Jared S. Hopkins In the latest setback for Moderna ...

Moderna shares were up 4.9% in premarket trading ... The stock is down 36% on the year. The biotech company said mNEXSPIKE was approved by the FDA for use in all adults ages 65 and up, as well ...